PDCD1 and non-small cell lung carcinoma: For instance, a prospective study of autoimmune dermatologic toxicity in patients who received anti–PD-1 therapy for non-small cell lung cancer (NSCLC) describes T-cell antigens shared between tumor tissue and skin.